{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:19:01Z","timestamp":1772165941840,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200896"],"award-info":[{"award-number":["82200896"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200896"],"award-info":[{"award-number":["82200896"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200896"],"award-info":[{"award-number":["82200896"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200896"],"award-info":[{"award-number":["82200896"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the increasing application of immune checkpoint inhibitors (ICI) in cancer therapy, the occurrence of isolated adrenocorticotropic hormone deficiency (IAD), as an adverse effect, is also on the rise. Nevertheless, there are only a few studies regarding IAD induced by ICI. This study aimed at investigating the characteristics of IAD induced by ICI and its relationship with other endocrine adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted in the Endocrinology Department from January 2019 to August 2022 to investigate characteristics of patients with IAD. Clinical features, laboratory findings and treatment information were collected. All patients underwent a follow-up of 3-6-month.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>28 patients with IAD were enrolled. All patients received treatment with anti-PD-1\/ PD-L1. The median occurrence time of IAD was 24 (18\u201339) weeks after initiation of ICI treatment. Over half of the patients (53.5%) had an additional endocrinopathy, including primary hypothyroidism and fulminant type 1 diabetes mellitus (FT1DM), while other types of endocrinopathies were not identified. The interval between the occurrences of two gland damages was between 4 and 21 weeks or simultaneous. Primary hypothyroidism (46.4%) was more prevalent than FT1DM (7.1%). Fatigue and nausea were common symptoms, with a frequent occurrence of hyponatremia. All patients continued on oral glucocorticoids during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IAD induced by ICI could manifest independently, or more frequently in combination with hypothyroidism or FT1DM. This damage could happen at any point of ICI treatment. Given that IAD can be life-threatening, it is critical to evaluate pituitary function dynamically in patients undergoing immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-023-01397-0","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:01:59Z","timestamp":1688601719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies"],"prefix":"10.1186","volume":"23","author":[{"given":"Hong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"issue":"7","key":"1397_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389\u201399.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1397_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev. 2019;40(1):17\u201365.","journal-title":"Endocr Rev"},{"key":"1397_CR3","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T et al. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer 2020, 8(2).","DOI":"10.1136\/jitc-2020-000779"},{"issue":"1","key":"1397_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12020-021-02750-w","volume":"74","author":"R Rubino","year":"2021","unstructured":"Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, Brugia M, Pimpinelli N, Antonuzzo L, Mini E, et al. Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. Endocrine. 2021;74(1):172\u20139.","journal-title":"Endocrine"},{"key":"1397_CR5","doi-asserted-by":"publisher","first-page":"847917","DOI":"10.3389\/fonc.2022.847917","volume":"12","author":"SA Paschou","year":"2022","unstructured":"Paschou SA, Liontos M, Eleftherakis-Papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, Zagouri F, Psaltopoulou T, Dimopoulos MA. Oncological patients with endocrine complications after Immunotherapy with checkpoint inhibitors present longer progression-free and overall survival. Front Oncol. 2022;12:847917.","journal-title":"Front Oncol"},{"issue":"4","key":"1397_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11102-006-0408-5","volume":"9","author":"M Andrioli","year":"2006","unstructured":"Andrioli M, Pecori Giraldi F, Cavagnini F. Isolated corticotrophin deficiency. Pituitary. 2006;9(4):289\u201395.","journal-title":"Pituitary"},{"issue":"6","key":"1397_CR7","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, Higham CE, Lupi I, Paschou SA, Toth M, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022;187(6):G1\u2013G21.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1397_CR8","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","volume":"6","author":"SA Paschou","year":"2021","unstructured":"Paschou SA, Stefanaki K, Psaltopoulou T, Liontos M, Koutsoukos K, Zagouri F, Lambrinoudaki I, Dimopoulos MA. How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open. 2021;6(1):100011.","journal-title":"ESMO Open"},{"key":"1397_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","volume":"5","author":"MH Tan","year":"2019","unstructured":"Tan MH, Iyengar R, Mizokami-Stout K, Yentz S, MacEachern MP, Shen LY, Redman B, Gianchandani R. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5:1.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"2","key":"1397_CR10","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364\u201389.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1397_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11154-005-5224-0","volume":"6","author":"MS Cooper","year":"2005","unstructured":"Cooper MS, Stewart PM. Diagnosis and treatment of ACTH deficiency. Rev Endocr Metab Disord. 2005;6(1):47\u201354.","journal-title":"Rev Endocr Metab Disord"},{"issue":"10274","key":"1397_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","volume":"397","author":"ES Husebye","year":"2021","unstructured":"Husebye ES, Pearce SH, Krone NP, Kampe O. Adrenal insufficiency. Lancet. 2021;397(10274):613\u201329.","journal-title":"Lancet"},{"issue":"8","key":"1397_CR13","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2337\/diacare.26.8.2345","volume":"26","author":"A Imagawa","year":"2003","unstructured":"Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26(8):2345\u201352.","journal-title":"Diabetes Care"},{"issue":"8","key":"1397_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/dmrr.1236","volume":"27","author":"A Imagawa","year":"2011","unstructured":"Imagawa A, Hanafusa T. Fulminant type 1 diabetes\u2013an important subtype in East Asia. Diabetes Metab Res Rev. 2011;27(8):959\u201364.","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"1397_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195\u2013207.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1397_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/jim-2021-002099","volume":"70","author":"A Kotwal","year":"2022","unstructured":"Kotwal A, Rouleau SG, Dasari S, Kottschade L, Ryder M, Kudva YC, Markovic S, Erickson D. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort. J Investig Med. 2022;70(4):939\u201346.","journal-title":"J Investig Med"},{"key":"1397_CR17","doi-asserted-by":"publisher","first-page":"578802","DOI":"10.3389\/fendo.2021.578802","volume":"12","author":"Y Fujita","year":"2021","unstructured":"Fujita Y, Bando H, Iguchi G, Iida K, Nishizawa H, Kanie K, Yoshida K, Matsumoto R, Suda K, Fukuoka H, et al. Clinical heterogeneity of acquired idiopathic isolated adrenocorticotropic hormone Deficiency. Front Endocrinol (Lausanne). 2021;12:578802.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1397_CR18","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Iwama S, Sugiyama D, Yasuda Y, Okuji T, Ito M, Ito S, Sugiyama M, Onoue T, Takagi H et al. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. J Immunother Cancer 2021, 9(5).","DOI":"10.1136\/jitc-2021-002493"},{"key":"1397_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","volume":"130","author":"S Yano","year":"2020","unstructured":"Yano S, Ashida K, Sakamoto R, Sakaguchi C, Ogata M, Maruyama K, Sakamoto S, Ikeda M, Ohe K, Akasu S, et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur J Cancer. 2020;130:198\u2013203.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1397_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","volume":"14","author":"G Di Dalmazi","year":"2019","unstructured":"Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metabolism. 2019;14(6):381\u201398.","journal-title":"Expert Rev Endocrinol Metabolism"},{"issue":"4","key":"1397_CR21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s11102-021-01141-8","volume":"24","author":"P Iglesias","year":"2021","unstructured":"Iglesias P, Sanchez JC, Diez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary. 2021;24(4):630\u201343.","journal-title":"Pituitary"},{"issue":"3","key":"1397_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11547-019-01120-x","volume":"125","author":"F Caranci","year":"2020","unstructured":"Caranci F, Leone G, Ponsiglione A, Muto M, Tortora F, Muto M, Cirillo S, Brunese L, Cerase A. Imaging findings in hypophysitis: a review. Radiol Med. 2020;125(3):319\u201328.","journal-title":"Radiol Med"},{"issue":"9","key":"1397_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"1397_CR24","doi-asserted-by":"crossref","unstructured":"Wright JJ, Johnson DB. Approach to the patient with Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction. J Clin Endocrinol Metab 2022.","DOI":"10.1210\/clinem\/dgac689"},{"issue":"3","key":"1397_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583\u20139.","journal-title":"Ann Oncol"},{"issue":"9","key":"1397_CR26","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM. Thyroid Immune-related adverse events following Immune checkpoint inhibitor treatment. J Clin Endocrinol Metab. 2021;106(9):e3704\u201313.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1397_CR27","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s40618-021-01508-5","volume":"44","author":"C Luongo","year":"2021","unstructured":"Luongo C, Morra R, Gambale C, Porcelli T, Sessa F, Matano E, Damiano V, Klain M, Schlumberger M, Salvatore D. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy. J Endocrinol Invest. 2021;44(9):1927\u201333.","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"1397_CR28","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","volume":"44","author":"L Brilli","year":"2021","unstructured":"Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabr\u00f2 L, Pilli T, Cartocci A, Pacini F, Di Giacomo AM, et al. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest. 2021;44(8):1719\u201326.","journal-title":"J Endocrinol Invest"},{"key":"1397_CR29","doi-asserted-by":"publisher","first-page":"1062679","DOI":"10.3389\/fimmu.2023.1062679","volume":"14","author":"T Mei","year":"2023","unstructured":"Mei T, Wang T, Deng Q, Gong Y. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: a systematic review and network meta-analysis. Front Immunol. 2023;14:1062679.","journal-title":"Front Immunol"},{"issue":"3","key":"1397_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and Meta-analysis of endocrine-related adverse events Associated with Immune Checkpoint inhibitors. Horm Metab Res. 2019;51(3):145\u201356.","journal-title":"Horm Metab Res"},{"key":"1397_CR31","doi-asserted-by":"publisher","first-page":"885001","DOI":"10.3389\/fpubh.2022.885001","volume":"10","author":"C Lin","year":"2022","unstructured":"Lin C, Li X, Qiu Y, Chen Z, Liu J. PD-1 inhibitor-associated type 1 diabetes: a case report and systematic review. Front Public Health. 2022;10:885001.","journal-title":"Front Public Health"},{"issue":"7","key":"1397_CR32","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.2337\/dc18-2518","volume":"42","author":"S Yoneda","year":"2019","unstructured":"Yoneda S, Imagawa A, Hosokawa Y, Baden MY, Kimura T, Uno S, Fukui K, Goto K, Uemura M, Eguchi H, et al. T-Lymphocyte infiltration to Islets in the Pancreas of a patient who developed type 1 diabetes after administration of Immune Checkpoint inhibitors. Diabetes Care. 2019;42(7):e116\u20138.","journal-title":"Diabetes Care"},{"key":"1397_CR33","doi-asserted-by":"publisher","first-page":"894015","DOI":"10.3389\/fonc.2022.894015","volume":"12","author":"A Chye","year":"2022","unstructured":"Chye A, Allen I, Barnet M, Burnett DL. Insights into the host contribution of Endocrine Associated Immune-Related adverse events to Immune Checkpoint Inhibition Therapy. Front Oncol. 2022;12:894015.","journal-title":"Front Oncol"},{"key":"1397_CR34","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2147\/DMSO.S353403","volume":"15","author":"M Li","year":"2022","unstructured":"Li M, Wu C, Liu Y, Zhang R, Yang Q, Shi Z, Sun W, Hu X. Autoimmune Polyendocrinopathy Induced by an antibody (KN046) that simultaneously inhibits PD-L1 and CTLA-4: a Case Report and Literature Review. Diabetes Metab Syndr Obes. 2022;15:1253\u201360.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"1397_CR35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMra1713301","volume":"378","author":"ES Husebye","year":"2018","unstructured":"Husebye ES, Anderson MS, Kampe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018;378(12):1132\u201341.","journal-title":"N Engl J Med"},{"issue":"4","key":"1397_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","volume":"66","author":"S Okahata","year":"2019","unstructured":"Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Noso S, Ikegami H, Shiba T. Fulminant type 1 diabetes associated with isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy. Endocr J. 2019;66(4):295\u2013300.","journal-title":"Endocr J"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01397-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01397-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01397-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:02:32Z","timestamp":1688601752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01397-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01397-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2604581\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"19 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written, informed consent was obtained from all of the participants, and the study was approved by the ethics committee of Zhongshan Hospital, Fudan University, China. All methods were carried out in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"139"}}